ABBV vs BMY
ABBV: A global biopharmaceutical leader focused on developing innovative, specialized therapies for immunology, oncology, neuroscience, and aesthetic medicine. BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally.
Side-by-side fundamentals
| Metric | ABBV | BMY | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $264.52 | $67.28 | |
| Market cap as of 2026-08-25 | $467.4B | $137.4B | |
| P/E as of 2026-08-25 | 70.24 | 14.21 | BMY lower |
| PEG as of 2026-08-25 | 6.59 | -8.67 | BMY lower |
| Net margin as of 2026-08-25 | +9.8% | +18.9% | BMY higher |
| Gross margin as of 2026-08-25 | +72.8% | +71.7% | ABBV higher |
| Operating margin as of 2026-08-25 | +26.2% | +25.5% | ABBV higher |
| ROE as of 2026-08-25 | +95.6% | +46.8% | ABBV higher |
| ROA as of 2026-08-25 | +4.7% | +10.3% | BMY higher |
| Debt / equity as of 2026-08-25 | 49.22 | 1.93 | BMY lower |
| Revenue growth (YoY) as of 2026-08-25 | +10.4% | +3.1% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | +1.4% | ABBV higher |
| Dividend yield as of 2026-08-25 | +4.5% | +4.6% | BMY higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-25 | 0.22 | 0.18 | |
| 1-year return as of 2026-08-24 close | +25.6% | +40.4% | BMY higher |
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.